10:54 AM
 | 
Jul 13, 2018
 |  BioCentury  |  Finance

Forbion builds immunity

Forbion’s fourth fund bumps up biotech allocation and continues to build newcos

With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in its portfolio companies’ life cycles, Forbion can avoid an increasingly competitive deal-making environment later on as the companies grow and raise more capital.

The VC raised €270 million ($317.8 million) on Wednesday toward Forbion IV, surpassing the fund’s €250 million ($294.2 million) target. Forbion’s Sander Slootweg expects the fund to close this fall around the mid-€300 million mark.

Forbion IV intends to fund the formation of five newcos and invest in...

Read the full 512 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >